Takeda Pharmaceutical (NYSE:TAK) Upgraded by Morgan Stanley to “Overweight” Rating

Morgan Stanley upgraded shares of Takeda Pharmaceutical (NYSE:TAK) from an equal weight rating to an overweight rating in a research report report published on Wednesday, MarketBeat.com reports.

Takeda Pharmaceutical Stock Up 0.5 %

NYSE TAK opened at $14.98 on Wednesday. Takeda Pharmaceutical has a 1-year low of $12.58 and a 1-year high of $15.31. The company has a market capitalization of $47.66 billion, a price-to-earnings ratio of 37.45, a PEG ratio of 0.24 and a beta of 0.46. The stock’s 50 day moving average is $14.27 and its two-hundred day moving average is $13.93. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.42 EPS for the quarter, beating the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. Equities analysts forecast that Takeda Pharmaceutical will post 1.64 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Takeda Pharmaceutical

Several institutional investors have recently added to or reduced their stakes in TAK. First Trust Advisors LP increased its holdings in shares of Takeda Pharmaceutical by 2.0% during the fourth quarter. First Trust Advisors LP now owns 3,240,932 shares of the company’s stock worth $42,910,000 after buying an additional 62,718 shares in the last quarter. FMR LLC increased its holdings in Takeda Pharmaceutical by 10.9% during the 3rd quarter. FMR LLC now owns 2,908,918 shares of the company’s stock valued at $41,365,000 after purchasing an additional 286,052 shares in the last quarter. Van ECK Associates Corp raised its position in Takeda Pharmaceutical by 1.6% in the 4th quarter. Van ECK Associates Corp now owns 2,210,428 shares of the company’s stock valued at $29,266,000 after purchasing an additional 35,192 shares during the last quarter. Northern Trust Corp boosted its stake in Takeda Pharmaceutical by 14.6% in the fourth quarter. Northern Trust Corp now owns 1,873,588 shares of the company’s stock worth $24,806,000 after purchasing an additional 238,161 shares in the last quarter. Finally, Soleus Capital Management L.P. grew its holdings in shares of Takeda Pharmaceutical by 136.0% during the fourth quarter. Soleus Capital Management L.P. now owns 1,180,000 shares of the company’s stock worth $15,623,000 after purchasing an additional 680,000 shares during the last quarter. 9.17% of the stock is owned by institutional investors.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.